276 related articles for article (PubMed ID: 24036693)
21. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
[TBL] [Abstract][Full Text] [Related]
22. Histopathology of BRCA1- and BRCA2-associated breast cancer.
Honrado E; Benítez J; Palacios J
Crit Rev Oncol Hematol; 2006 Jul; 59(1):27-39. PubMed ID: 16530420
[TBL] [Abstract][Full Text] [Related]
23. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.
Pinilla SM; Honrado E; Hardisson D; Benítez J; Palacios J
Breast Cancer Res Treat; 2006 Sep; 99(1):85-90. PubMed ID: 16541313
[TBL] [Abstract][Full Text] [Related]
24. Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions.
Chene G; Tchirkov A; Pierre-Eymard E; Dauplat J; Raoelfils I; Cayre A; Watkin E; Vago P; Penault-Llorca F
Clin Cancer Res; 2013 Jun; 19(11):2873-82. PubMed ID: 23589176
[TBL] [Abstract][Full Text] [Related]
25. Next-Generation Sequencing Identifies
Peker Eyüboğlu İ; Yenmiş G; Bingöl EN; Yüksel Ş; Tokat F; Özbek P; Güllü Amuran G; Yakıcıer C; Akkiprik M
OMICS; 2020 Jan; 24(1):5-15. PubMed ID: 31851867
[TBL] [Abstract][Full Text] [Related]
26. Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes.
Melchor L; Honrado E; García MJ; Alvarez S; Palacios J; Osorio A; Nathanson KL; Benítez J
Oncogene; 2008 May; 27(22):3165-75. PubMed ID: 18071313
[TBL] [Abstract][Full Text] [Related]
27. Telomere shortening in breast cancer correlates with the pathological features of tumor progression.
Kammori M; Sugishita Y; Okamoto T; Kobayashi M; Yamazaki K; Yamada E; Yamada T
Oncol Rep; 2015 Aug; 34(2):627-32. PubMed ID: 26080929
[TBL] [Abstract][Full Text] [Related]
28. Genetic anticipation is associated with telomere shortening in hereditary breast cancer.
Martinez-Delgado B; Yanowsky K; Inglada-Perez L; Domingo S; Urioste M; Osorio A; Benitez J
PLoS Genet; 2011 Jul; 7(7):e1002182. PubMed ID: 21829373
[TBL] [Abstract][Full Text] [Related]
29. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
30. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
31. Telomere length alterations unique to invasive lobular carcinoma.
Heaphy CM; Asch-Kendrick R; Argani P; Meeker AK; Cimino-Mathews A
Hum Pathol; 2015 Aug; 46(8):1197-203. PubMed ID: 26092192
[TBL] [Abstract][Full Text] [Related]
32. The molecular pathology of hereditary breast cancer.
Palacios J; Robles-Frías MJ; Castilla MA; López-García MA; Benítez J
Pathobiology; 2008; 75(2):85-94. PubMed ID: 18544963
[TBL] [Abstract][Full Text] [Related]
33. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A
Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844
[TBL] [Abstract][Full Text] [Related]
34. Shorter telomere length is associated with increased ovarian cancer risk in both familial and sporadic cases.
Martinez-Delgado B; Yanowsky K; Inglada-Perez L; de la Hoya M; Caldes T; Vega A; Blanco A; Martin T; Gonzalez-Sarmiento R; Blasco M; Robledo M; Urioste M; Song H; Pharoah P; Benitez J
J Med Genet; 2012 May; 49(5):341-4. PubMed ID: 22493152
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
[TBL] [Abstract][Full Text] [Related]
36. Telomere-mediated genomic instability and the clinico-pathological parameters in breast cancer.
Poonepalli A; Banerjee B; Ramnarayanan K; Palanisamy N; Putti TC; Hande MP
Genes Chromosomes Cancer; 2008 Dec; 47(12):1098-109. PubMed ID: 18720522
[TBL] [Abstract][Full Text] [Related]
37. The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer.
Jönsson G; Staaf J; Vallon-Christersson J; Ringnér M; Gruvberger-Saal SK; Saal LH; Holm K; Hegardt C; Arason A; Fagerholm R; Persson C; Grabau D; Johnsson E; Lövgren K; Magnusson L; Heikkilä P; Agnarsson BA; Johannsson OT; Malmström P; Fernö M; Olsson H; Loman N; Nevanlinna H; Barkardottir RB; Borg Å
Cancer Res; 2012 Aug; 72(16):4028-36. PubMed ID: 22706203
[TBL] [Abstract][Full Text] [Related]
38. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
39. Prognostic role of HuR in hereditary breast cancer.
Heinonen M; Fagerholm R; Aaltonen K; Kilpivaara O; Aittomäki K; Blomqvist C; Heikkilä P; Haglund C; Nevanlinna H; Ristimäki A
Clin Cancer Res; 2007 Dec; 13(23):6959-63. PubMed ID: 18056170
[TBL] [Abstract][Full Text] [Related]
40. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.
Pharoah PD; Easton DF; Stockton DL; Gayther S; Ponder BA
Cancer Res; 1999 Feb; 59(4):868-71. PubMed ID: 10029077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
